UNC Pleural Fluid Registry

UNC Lineberger Comprehensive Cancer Center (Other)
Overall Status
CT.gov ID

Study Details

Study Description

Brief Summary

Research with biospecimens such as blood, tissue, or body fluids can help researchers understand how the human body works. Researchers can make new tests to find diseases, understand how treatments work, or find new ways to treat a disease. The purpose of this study is to collect biospecimens for research from patients with known or suspected lung cancer. The information learned from the biospecimens may be used in future treatments. The purpose of this protocol is to create a pleural fluid registry for use in future studies.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    9999 participants
    Observational Model:
    Time Perspective:
    Official Title:
    University of North Carolina Pleural Fluid Registry
    Actual Study Start Date :
    Jan 24, 2018
    Anticipated Primary Completion Date :
    Jan 24, 2050
    Anticipated Study Completion Date :
    Jan 24, 2050

    Arms and Interventions

    Arm Intervention/Treatment
    Pleural Fluid Registry

    Any subject who has pleural fluid buildup from lung cancer, breast cancer, or lung infection

    Outcome Measures

    Primary Outcome Measures

    1. Creation of a pleural fluid registry [32 years]

      Biological specimens and corresponding clinical data from subjects will be collected during standard of care procedures and medical record abstraction to support the creation of a pleural fluid registry.

    Eligibility Criteria


    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Accepts Healthy Volunteers:
    Inclusion Criteria:
    • Patients who are 18 years or older

    • Inpatients and outpatients

    • Diagnosed with pleural fluid, are referred for and undergo clinically indicated drainage who have clinical evidence of:

    • pulmonary infection (such as fever, leukocytosis, new or worsening infiltrate on chest x-ray, or clinical deterioration) with effusion

    • malignancy

    Exclusion Criteria:
    • A subject will not be eligible for inclusion in this registry if, in the investigator's (or treating clinician's) opinion, the patient has any concurrent medical condition that may preclude their ability to undergo pleural fluid drainage safely.

    • Incarcerated individuals

    Contacts and Locations


    Site City State Country Postal Code
    1 UNC Lingeberger Comprehensive Cancer Center Chapel Hill North Carolina United States 27599

    Sponsors and Collaborators

    • UNC Lineberger Comprehensive Cancer Center


    • Principal Investigator: Jason Akulian, UNC Lineberger Comprehensive Cancer Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:


    None provided.
    Responsible Party:
    UNC Lineberger Comprehensive Cancer Center
    ClinicalTrials.gov Identifier:
    Other Study ID Numbers:
    • LCCC1754
    First Posted:
    Nov 17, 2022
    Last Update Posted:
    Nov 17, 2022
    Last Verified:
    Nov 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Plan to Share IPD:
    Studies a U.S. FDA-regulated Drug Product:
    Studies a U.S. FDA-regulated Device Product:
    Keywords provided by UNC Lineberger Comprehensive Cancer Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 17, 2022